Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1960 1
1961 5
1963 2
1964 1
1965 2
1966 2
1968 3
1969 5
1970 7
1971 5
1972 2
1973 3
1974 8
1975 7
1976 3
1977 13
1978 12
1979 5
1980 6
1981 9
1982 12
1983 14
1984 19
1985 15
1986 34
1987 25
1988 22
1989 38
1990 42
1991 39
1992 21
1993 26
1994 28
1995 29
1996 39
1997 36
1998 39
1999 38
2000 49
2001 50
2002 62
2003 70
2004 78
2005 85
2006 68
2007 75
2008 77
2009 78
2010 70
2011 78
2012 88
2013 98
2014 93
2015 94
2016 96
2017 110
2018 85
2019 93
2020 88
2021 109
2022 75
Text availability
Article attribute
Article type
Publication date

Search Results

2,292 results
Results by year
Filters applied: . Clear all
Page 1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: yano s. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: yano s. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
In Reply.
Arai S, Yano S. Arai S, et al. Among authors: yano s. J Thorac Oncol. 2020 Jun;15(6):e93. doi: 10.1016/j.jtho.2020.03.010. J Thorac Oncol. 2020. PMID: 32471570 Free article. No abstract available.
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C. Sheng J, et al. Among authors: yano s. Hepatology. 2021 Oct;74(4):1971-1993. doi: 10.1002/hep.31872. Epub 2021 Aug 25. Hepatology. 2021. PMID: 33931882
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, Hotta K, Sato M, Matsumoto S, Tanimoto A, Matsuzawa R, Kiura K, Takashima Y, Yano S, Koyama J, Fukushima T, Hamamoto J, Terai H, Ikemura S, Takemura R, Goto K, Soejima K. Yasuda H, et al. Among authors: yano s. Lung Cancer. 2021 Dec;162:140-146. doi: 10.1016/j.lungcan.2021.10.006. Epub 2021 Oct 16. Lung Cancer. 2021. PMID: 34808485 Clinical Trial.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Okura N, et al. Among authors: yano s. Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953310
De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.
Weng PL, Majmundar AJ, Khan K, Lim TY, Shril S, Jin G, Musgrove J, Wang M, Ahram DF, Aggarwal VS, Bier LE, Heinzen EL, Onuchic-Whitford AC, Mann N, Buerger F, Schneider R, Deutsch K, Kitzler TM, Klämbt V, Kolb A, Mao Y, Moufawad El Achkar C, Mitrotti A, Martino J, Beck BB, Altmüller J, Benz MR, Yano S, Mikati MA, Gunduz T, Cope H, Shashi V; Undiagnosed Diseases Network, Trachtman H, Bodria M, Caridi G, Pisani I, Fiaccadori E, AbuMaziad AS, Martinez-Agosto JA, Yadin O, Zuckerman J, Kim A; UCLA Clinical Genomics Center, John-Kroegel U, Tyndall AV, Parboosingh JS, Innes AM, Bierzynska A, Koziell AB, Muorah M, Saleem MA, Hoefele J, Riedhammer KM, Gharavi AG, Jobanputra V, Pierce-Hoffman E, Seaby EG, O'Donnell-Luria A, Rehm HL, Mane S, D'Agati VD, Pollak MR, Ghiggeri GM, Lifton RP, Goldstein DB, Davis EE, Hildebrandt F, Sanna-Cherchi S. Weng PL, et al. Among authors: yano s. Am J Hum Genet. 2021 Feb 4;108(2):357-367. doi: 10.1016/j.ajhg.2021.01.008. Epub 2021 Jan 27. Am J Hum Genet. 2021. PMID: 33508234 Free PMC article.
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Among authors: yano s. Cancers (Basel). 2021 Aug 5;13(16):3958. doi: 10.3390/cancers13163958. Cancers (Basel). 2021. PMID: 34439111 Free PMC article.
2,292 results